Magainin Pharmaceuticals Inc.
Records under this name other than patents Magainin Pharmaceuticals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Magainin Pharmaceuticals Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,261,559 | Methods of treating asthma with interleukin-9 antibodies Formerly held Term ended Term ended Jun 4, 2019 · From the USPTO record | Term ended | Term ended Jun 4, 2019 | From the USPTO record |
| US 6,610,866 | Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds Formerly held Term ended Term ended Mar 22, 2018 · From the USPTO record | Term ended | Term ended Mar 22, 2018 | From the USPTO record |
| US 6,262,283 | Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds Formerly held Term ended Term ended Dec 5, 2017 · From the USPTO record | Term ended | Term ended Dec 5, 2017 | From the USPTO record |
| US 6,399,370 | Compositions and methods for use of defensin Term ended Term ended Aug 20, 2017 · From the USPTO record | Term ended | Term ended Aug 20, 2017 | From the USPTO record |
| US 6,147,060 | Treatment of carcinomas using squalamine in combination with other anti-cancer agents Formerly held Term ended Term ended Apr 25, 2017 · From the USPTO record | Term ended | Term ended Apr 25, 2017 | From the USPTO record |
| US 6,596,712 | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities Formerly held Term ended Term ended Apr 25, 2017 · From the USPTO record | Term ended | Term ended Apr 25, 2017 | From the USPTO record |
| US 6,037,149 | DNA encoding human asthma associated factor 1 Formerly held Term ended Term ended Aug 23, 2016 · From the USPTO record | Term ended | Term ended Aug 23, 2016 | From the USPTO record |
| US 6,645,492 | Methods of treating asthma with interleukin-9 receptor antibodies Formerly held Lapsed on the fee record Ended Nov 11, 2015 · From the USPTO record | Lapsed on the fee record | Ended Nov 11, 2015 | From the USPTO record |
| US 6,602,850 | Method of treating asthma using soluble IL-9 receptor variants Formerly held Lapsed on the fee record Ended Aug 5, 2015 · From the USPTO record | Lapsed on the fee record | Ended Aug 5, 2015 | From the USPTO record |
| US 6,962,909 | Treatment of neovascularization disorders with squalimine Formerly held Term ended Term ended Jun 22, 2015 · From the USPTO record | Term ended | Term ended Jun 22, 2015 | From the USPTO record |